Xu Yun, Fu Li, Gu Feng, Ma Yong-jie
Central Laboratory Department of Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zhonghua Zhong Liu Za Zhi. 2012 Mar;34(3):205-9. doi: 10.3760/cma.j.issn.0253-3766.2012.03.010.
To detect the expression of phosphorylated girdin (p-girdin) in breast cancer and its association with pathological characteristics and molecular subtypes of breast cancer.
Immunohistochemical SP staining was used to investigate the expression of p-girdin in 27 cases of lobular hyperplasia of mammary gland, 61 cases of ductal carcinoma in situ (DCIS), and 94 cases of non-special type invasive carcinoma (IDC-NOS) of breast.
p-girdin was located in the cell cytoplasm and (or) nuclei in breast cancer. There was statistically a very significant difference among lobular hyperplasia, DCIS and IDC-NOS (χ2=26.724, P<0.001). Its cytoplasmic and nuclear reactivity were 25.9% (7/27), 39.3% (24/61), and 66.0% (62/94), respectively. The expression of p-girdin was positively associated with pathologic stage (r=0.204, P=0.049), lymph node metastasis (r=0.212, P=0.041) and HER2/neu (r=0.248, P=0.016). But no significant association was identified between p-girdin expression and histological grade (r=-0.015, P=0.918), age of patients (r=-0.011, P=0.918), tumor size (r=0.075, P=0.471), ER(r=0.071, P=0.498), PR (r=-0.050, P=0.634). Mann-Whitney test showed that p-girdin expression in luminal A, luminal B, triple negative and HER-2(+) type was significantly different (χ2=14.017, P=0.003). Among the four types, its positive rate was 55.8% (24/43), 95.8% (23/24), 66.7% (10/15), and 41.7% (5/12), respectively.
p-Girdin expression is closely correlated with the malignant progression of breast cancer. Its expression may have clinical value as a new target for the treatment of breast cancer.
检测磷酸化的Girdin（p-Girdin）在乳腺癌中的表达及其与乳腺癌病理特征和分子亚型的关系。
采用免疫组织化学SP染色法检测27例乳腺小叶增生、61例导管原位癌（DCIS）和94例乳腺非特殊类型浸润性癌（IDC-NOS）中p-Girdin的表达。
p-Girdin在乳腺癌细胞的细胞质和（或）细胞核中表达。小叶增生、DCIS和IDC-NOS之间差异有统计学意义（χ2=26.724，P<0.001）。其细胞质和细胞核反应率分别为25.9%（7/27）、39.3%（24/61）和66.0%（62/94）。p-Girdin的表达与病理分期（r=0.204，P=0.049）、淋巴结转移（r=0.212，P=0.041）和HER2/neu（r=0.248，P=0.016）呈正相关。但p-Girdin表达与组织学分级（r=-0.015，P=0.918）、患者年龄（r=-0.011，P=0.918）、肿瘤大小（r=0.075，P=0.471）、雌激素受体（ER，r=0.071，P=0.498）、孕激素受体（PR，r=-0.050，P=0.634）之间无显著相关性。Mann-Whitney检验显示，p-Girdin在腔面A型、腔面B型、三阴性和HER-2（+）型中的表达有显著差异（χ2=14.017，P=0.003）。在这四种类型中，其阳性率分别为55.8%（24/43）、95.8%（23/24）、66.7%（10/15）和41.7%（5/12）。
p-Girdin表达与乳腺癌的恶性进展密切相关。其表达可能作为乳腺癌治疗的新靶点具有临床价值。
